Sugi Predict

Sugi Predict / Compounds / SCHEMBL40102

SCHEMBL40102

SCHEMBL40102

CC(N)c1cccc(C(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 1/20 0.58
▸ HTR2C P28335 1/20 0.58
▸ HTR2B P41595 1/20 0.58
▸ PNMT P11086 1/20 0.56
▸ IDO1 P14902 1/20 0.53
▸ TDO2 P48775 1/20 0.53
▸ TSHR P16473 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ DAO P14920 1/20 0.49
▸ CES2 O00748 1/20 0.47
▸ ACP3 P15309 1/20 0.47
▸ TACR1 P25103 1/20 0.46
▸ OPRM1 P35372 2/20 0.46
▸ OPRD1 P41143 2/20 0.46
▸ OPRK1 P41145 2/20 0.46
▸ OPRL1 P41146 2/20 0.46
▸ EPHX1 P07099 1/20 0.45
▸ SLC6A2 P23975 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ PDE2A O00408 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334964 1.00 HTR2A (0.58) HTR2AHTR2CHTR2BPNMTIDO1
SCHEMBL29504910 1.00 HTR2A (0.58) HTR2AHTR2CHTR2BPNMTIDO1
SCHEMBL1728826 1.00 HTR2A (0.58) HTR2AHTR2CHTR2BPNMTIDO1
Hydrochloric Acid SCHEMBL14121095 0.98 HTR2A (0.56) HTR2AHTR2CHTR2BPNMTIDO1
Methane SCHEMBL8899008 0.98 HTR2A (0.56) HTR2AHTR2CHTR2BPNMTIDO1
Hydrochloric Acid SCHEMBL23246369 0.98 HTR2A (0.56) HTR2AHTR2CHTR2BPNMTIDO1
Hydrochloric Acid SCHEMBL7787892 0.98 HTR2A (0.56) HTR2AHTR2CHTR2BPNMTIDO1
SCHEMBL10913587 0.94 IDO1 (0.57) HTR2AHTR2CHTR2BPNMTIDO1
SCHEMBL18266127 0.86 PDE2A (0.47) HTR2AHTR2CHTR2BPNMTIDO1
SCHEMBL18266126 0.86 PDE2A (0.47) HTR2AHTR2CHTR2BPNMTIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116444447-B SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof 中国药科大学 2023-09-22 — — CN claimed
EP-3688131-B1 COMPOSITIONS AND METHODS FOR PREVENTING COLLAPSE OF HIGH ASPECT RATIO STRUCTURES DURING DRYING VERSUM MAT US LLC (US) 2023-08-09 — — EP claimed
CN-116444447-A SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof 中国药科大学 2023-07-18 — — CN claimed
US-10954480-B2 Compositions and methods for preventing collapse of high aspect ratio structures during drying VERSUM MATERIALS US, LLC (US) 2021-03-23 — — US claimed
US-20130143824-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2013-06-06 — — US claimed
US-20120058953-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2012-03-08 — — US claimed
US-20110039324-A1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH, INC. (US) 2011-02-17 — — US claimed
US-20090148921-A1 Compositions and methods for enhancing apoptosis GENENTECH, INC. (US) 2009-06-11 — — US claimed
EP-1590666-B1 COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS GENENTECH INC (US) 2008-07-09 — — EP claimed
US-20040171554-A1 Compositions and methods for enhancing apoptosis GENENTECH, INC. 2004-09-02 — — US claimed
EP-0403360-A2 Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders SANOFI (FR) 1990-12-19 — — EP claimed
EP-0255415-A2 Use of phenylethanolamines for the preparation of medicaments acting on gastrointestinal troubles ELF SANOFI (FR) 1988-02-03 — — EP claimed
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
WO-2025213277-A1 N1-(3,4-DICHLOROPHENYL)MALEAMIDE DERIVATIVES AND THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY DISORDERS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-10-16 — — WO disclosed
US-20250197407-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE 2025-06-19 — — US disclosed
US-20250154147-A1 NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE 2025-05-15 — — US disclosed
US-6197803-B1 VIRICIDES; PREVENTION REPRODUCTION AMERICAN HOME PRODUCTS CORPORATION 2001-03-06 — — US disclosed
EP-1070703-A1 Cyclobutene derivatives Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed
US-6166028-A Diaminopuridine-containing thiourea inhibitors of herpes viruses AMERICAN HOME PRODUCTS CORPORATION (US) 2000-12-26 — — US disclosed
CN-1033797-A The N-phenylalkylbenzamidefungicides fungicides LILLY CO ELI (US) 1989-07-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154147-A1 NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS SOS1, SOS2, SOST HTR2A 2741/4885HTR2C 3413/4885HTR2B 3261/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 HTR2A 4098/4885HTR2C 3202/4885HTR2B 3387/4885
US-20250197407-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS SOS1, SOS2, SOST HTR2A 3172/4885HTR2C 3326/4885HTR2B 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.